ASCO clinical practice guidelines for HER2-positive breast cancer
The American Society of Clinical Oncology (ASCO) has updated its clinical practice guidelines on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2)–positive advanced breast cancer published online June 25, 2015 in the Journal of Clinical Oncology. As per the guideline, HER2-targeted therapy is recommended for patients with HER2-positive advanced breast cancer, except for patients with clinical congestive heart failure or significantly compromised left ventricular ejection fraction, who should be evaluate
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies